A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects
Sponsor: Eli Lilly and Company
Listed as NCT01436201, this PHASE1 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .